WuXi ATU and GeneMedicine Collaborate to Develop and Manufacture Oncolytic Virus Products
- WuXi ATU to provide overall process development- viral bank manufacturing- viral stock characterization and cGMP commercial manufacturing and IND filing services via its Oncolytic Virus CDMO platform- to accelerate the development and commercialization of Gene Medicine's oncolytic virus products
- The collaboration allows GeneMedicine to advance its pipeline products from the clinical stage to commercialization by utilizing WuXi ATU’s platform covering all types of products with high quality that obey global standards
- The collaboration is the first international CMC development and manufacturing project- emboldened by the Oncolytic Virus CDMO platform- jointly operated by WuXi ATU and GeneSail Biotech since Aug’2019
Click here to read full press release/ article | Ref: PRNewswire | Image: WuXi ATU
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].